ARQ 197: all 43 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Tivantinib in Treating Patients With Previously Treated Malignant MesotheliomaTerminatedNCT01861301Phase 2Results posted
- Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior TherapyCompletedNCT01755767Phase 3Results posted
- Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by SurgeryCompletedNCT01696955Phase 2Results posted
- Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or StomachCompletedNCT01611857Phase 1/2Results posted
- Tivantinib in Treating Patients With Recurrent or Metastatic Breast CancerCompletedNCT01575522Phase 2Results posted
- Tivantinib in Treating Patients With Metastatic Prostate CancerCompletedNCT01519414Phase 2Results posted
- Pazopanib and ARQ 197 for Advanced Solid TumorsCompletedNCT01468922Phase 1Results posted
- Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple MyelomaCompletedNCT01447914Phase 2Results posted
- Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT01395758Phase 2Results posted
- Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung CancerTerminatedNCT01244191Phase 3Results posted
- An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) ProtocolsCompletedNCT01178411Phase 1/2Results posted
- ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal CancerCompletedNCT01075048Phase 1/2Results posted
- ARQ 197 for Participants With Relapsed or Refractory Germ Cell TumorsTerminatedNCT01055067Phase 2Results posted
- TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)TerminatedNCT02608411Phase 2
- Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic ImpairmentCompletedNCT02150733Phase 1
- Study of the Combination of Tivantinib Plus Pemetrexed and CarboplatinCompletedNCT02049060Phase 1/2
- A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)CompletedNCT02029157Phase 3
- Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High SubjectsCompletedNCT01892527Phase 2
- Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT01749384Phase 1
- Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid TumorsCompletedNCT01725191Phase 1
- Effect of Tivantinib on the QTC Interval in Cancer SubjectsCompletedNCT01699061Phase 1
- Study of ARQ 197 in Hepatocellular Carcinoma (HCC)CompletedNCT01656265Phase 1
- Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid TumorsCompletedNCT01654965Phase 1
- Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by SurgeryCompletedNCT01625156Phase 1
- ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung CancerCompletedNCT01580735Phase 2
- Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer SubjectsCompletedNCT01517399Phase 1
- A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus ErlotinibTerminatedNCT01377376Phase 3
- A Study of ARQ 197 in Combination With ErlotinibCompletedNCT01251796Phase 1
- Study of ARQ 197 MonotherapyCompletedNCT01152645Phase 2
- Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid TumorsCompletedNCT01149720Phase 1
- A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy RegimenWithdrawnNCT01070290Phase 2
- A Study of ARQ 197 in Combination With ErlotinibCompletedNCT01069757Phase 1
- Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic TherapyCompletedNCT00988741Phase 2
- Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)CompletedNCT00802555Phase 1
- A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00777309Phase 2
- Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy VolunteersCompletedNCT00658554Phase 1
- A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) GenotypeCompletedNCT00651638Phase 1
- A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid TumorsCompletedNCT00612703Phase 1
- A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid TumorsCompletedNCT00612209Phase 1
- A Phase 1 Study of ARQ 197 in Patients With Solid TumorsCompletedNCT00609921Phase 1
- A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic AdenocarcinomaCompletedNCT00558207Phase 2
- Phase 2 Study in Patients With MiT TumorsCompletedNCT00557609Phase 2
- ARQ 197 in Subjects With Metastatic Solid TumorsCompletedNCT00302172Phase 1